Prognostic role of the skeletal musculature in oncology: significance, coherences and clinical implications

Prognostische Rolle der Skelettmuskulatur in der Onkologie: Bedeutung, Zusammenhänge und klinische Implikationen

Authors
Alexey Surov, Andreas Wienke, Ralf Gutzmer, Jan Borggrefe

Affiliations
1 Department of Radiology, Neuroradiology and Nuclear Medicine, Johannes Wesling Medical Center, Ruhr University Bochum, Germany
2 Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin Luther University Halle Wittenberg, Halle, Germany
3 Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, Germany

Key words
sarcopenia, cancer, survival

received 10.7.2023
accepted 2.11.2023
published online 2023

Bibliography
Fortschr Röntgenstr
DOI 10.1055/a-2213-2320
ISSN 1438-9029
© 2023, Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Correspondence
Herr Prof. Alexey Surov
Department of Radiology, Neuroradiology and Nuclear Medicine, Johannes Wesling Hospital Minden, Hans-Nolte Str 1, 44801 Minden, Germany
Tel.: +49/5 71/79 00
Alexey.Surov@muehlenkreiskliniken.de

ABSTRACT

Background Sarcopenia is defined as a loss of muscle mass and strength as well as decreased physical performance. Method The present study provides a systematic overview of the current literature in regard to the prognostic role of sarcopenia in oncology. Conclusion In oncologic patients, sarcopenia occurs in 39.6 % of cases in a curative setting and in 49.2 % in a palliative setting. Sarcopenia is associated with dose-limiting toxicity. Furthermore, sarcopenia is associated with the occurrence of postoperative complications. Also, reduced muscle mass limits overall survival in most tumors both in a curative and a palliative setting. Therefore, analysis of the skeletal musculature on staging CT should be implemented in the clinical routine in oncology.

Key Points:
▪ In oncologic patients, the prevalence of sarcopenia is 39.6 % in a curative setting and 49.2 % in a palliative setting.
▪ Sarcopenia is associated with dose-limiting toxicity and treatment response.
▪ Sarcopenia predicts overall survival in oncologic patients.

Citation Format

ZUSAMMENFASSUNG

Hintergrund Sarkopenie ist durch einen Verlust von Muskelkraft, Muskelmasse und –funktion charakterisiert. Sie ist ein sehr häufiges Syndrom bei onkologischen Patienten, quantitativ messbar und prognostisch bei vielen Tumorentitäten klinisch relevant.

Methoden Mit einer systematischen Analyse der publizierten Meta-Analysen gibt die vorliegende Arbeit eine Übersicht zum aktuellen Kenntnisstand und der prognostischen Rolle der Sarkopenie in der Onkologie.

Background

Sarcopenia is characterized by a loss of muscle strength, mass, and function [1]. Sarcopenia is common in patients with advanced malignant diseases [2, 3]. Due to the high prevalence of sarcopenia, it is currently the subject of intensive research. In oncological visceral surgery, sarcopenia can be a better predictor of 1-year mortality, morbidity, and postoperative complications in various diseases compared to other physiological reserve metrics like the “frailty index” and the Eastern Cooperative Oncology Group (ECOG) score. Therefore, sarcopenia is more important as a predictive factor than disease-specific scores [4, 5]. Moreover, a connection between pretherapeutic sarcopenia and toxicity of various chemotherapies was observed [6].

When staging oncological patients, imaging methods can provide quick and objective evaluation of skeletal muscle quality and quantity. In the case of computed tomography as a frequently used imaging method, calculations of skeletal muscle mass are usually based on the total area of all skeletal muscles on the axial plane at the level of L3 [7–9] (Fig. 1). With AI, these measurements can already be performed fully automatically by prototypes in that skeleton segmentation, automatic slice selection, and slice-specific segmentation of the musculature at the level of L3 are performed. The muscle area determined based on the CT slice at the level of L3 correlates very well with the total body muscle mass [7, 9–12]. Segmentation of skeletal muscle on computed tomography is performed based on the HU values. Thus, a muscle-specific cut-off value of -29 to +150 HU is used for measuring muscle tissue [7, 9, 10]. On magnetic resonance imaging, muscle segmentation is performed based on the contrast between muscle tissue and fat. Primarily T1-weighted sequences and sequences with which the fat and water content can be quantified (Dixon sequences) are used to visualize the muscle morphology (Fig. 2). The skeletal muscle index (SMI) can be calculated from the muscle area and the body size (SMI = muscle area [cm²]/body size [m] squared) [7, 9–12]. The muscle area can be determined on staging CT or MRI images with the help of both commercial and free computer programs and is now performed in the clinical routine.

Various cut-off values for the determination of reduced muscle mass are published in the literature (Table 1). The present study describes the role of sarcopenia in oncology and provides an overview of the current scientific results.

Prevalence of sarcopenia in oncology

Sarcopenia is very common in cancer patients. The prevalence of sarcopenia is 39.6 % in the curative setting and 49.2 % in the palliative setting [13] and varies between the individual tumor entities (Table 2). Patients with esophageal cancer, cholangiocarcinoma, sarcomas, prostate cancer, and urothelial carcinoma frequently have concomitant sarcopenia (>50 % in each case).

Prognostic role of sarcopenia in oncology

Sarcopenia is considered a causal factor and not just an epiphenomenon of cancer diseases. In addition to its broad prevalence in the population, sarcopenia can be caused by different factors like impaired food intake due to an obstructive tumor, insufficient food intake, alcohol and tobacco consumption, and tumor-associated inflammation [3, 4, 10]. Moreover, chemotherapeutic agents can damage skeletal muscle. Finally, skeletal muscle interacts intensively with the immune system and produces specific cytokines and peptides that have positive immunological effects and thus affect the course of the disease and treatment [3, 4, 9, 10].
Sarcopenia and dose-limiting toxicity

In accordance with the current literature, sarcopenia is highly associated with dose-limiting toxicity (DLT) of medication-based tumor therapies. In the curative setting, patients with reduced muscle mass have a higher risk of developing DLT compared to patients with normal muscle mass (OR = 2.48, 95% CI (1.77–3.48), p < 0.0001) [6].

Sarcopenia has a significant effect on DLT also in the palliative setting. In patients undergoing conventional chemotherapy, the effect of sarcopenia is moderate: OR = 2.14, 95% CI (1.38–3.31), p = 0.0006 [6]. The effect of sarcopenia is measurably greater in patients receiving different kinase inhibitors: OR = 3.08, 95% CI (1.87–5.09), p = 0.0001 [6]. In contrast, sarcopenia has no relevant effect on DLT in the case of immunotherapies: OR = 1.30, 95% CI (0.79–2.11), p = 0.3 [6].

Sarcopenia and treatment response

Sarcopenia is a highly significant predictive factor for the objective response rate of chemotherapies in the curative setting: OR = 0.24, 95% CI (0.12–0.50), p = 0.0001 [14]. In conventional palliative chemotherapy, sarcopenia does not play a predictive role for the objective response rate according to the current results of meta-analyses: OR = 0.94, 95% CI (0.57–1.55), p = 0.81 [14]. The reduced muscle mass also has no prognostic significance for the prediction of treatment response in patients receiving palliative treatment with kinase inhibitors: OR = 0.74, 95% CI (0.44–1.26), p = 0.27 [14]. In relation to palliative immunotherapies, the objective response rate did not have any predictive power: OR = 0.74, 95% CI (0.54–1.01), p = 0.06 [14].

Sarcopenia and postoperative complications

Sarcopenia is highly associated with severe postoperative complications in diverse gastrointestinal tumors, RR = 1.40, 95% CI (1.20–1.64), p < 0.001 [5]. The greatest effect was observed in patients with gastric cancer, RR = 1.97, 95% CI (1.11–3.51), p = 0.02 [5]. In contrast, sarcopenia had no relevant effect on postoperative complications in patients with colon cancer and esophageal cancer [5].

Sarcopenia and survival

In the curative setting, reduced muscle mass has a significant effect on overall survival [15]. The maximum negative effect of sarcopenia was reported in bronchial carcinoma followed by urothelial carcinoma and squamous cell carcinoma in the head/neck region (Table 3). In the case of hepatocellular carcinoma, pancreatic cancer, cholangiocarcinoma, squamous cell carcinoma of the head/neck region, and gastric cancer, sarcopenia is an independent predictive factor for overall survival. Sarcopenia also has a significant effect on disease-free survival in most cancers (Table 3). This effect is particularly pronounced in squamous cell carcinoma of the head/neck region, cholangiocarcinoma, gastric cancer, and hepatocellular carcinoma.

Sarcopenia is also prognostically significant in the palliative setting. However, its influence on overall survival is less pronounced than in the curative setting (Table 4). In colorectal cancer, urothelial carcinoma, hepatocellular carcinoma, prostate cancer, and pancreatic cancer, reduced muscle mass is an independent parameter influencing overall survival.

Sarcopenia also has a relevant effect on progression-free survival in renal cell carcinoma, urothelial carcinoma, bronchial carcinoma, and ovarian cancer (Table 4).

Discussion

The current studies presented in this review article show that sarcopenia is a prognostically relevant factor in oncology. It can be measured in a cost-effective manner during staging and is a reproducible and quantifiable parameter. The diagnosis of sarco-
The phenomenon of sarcopenia predicting the toxicity of onco-
ological treatment in patients with carcinomas is indeed elevated [25–27]. Studies have shown that the plasma concentration of diverse chemotherapeutic agents in patients with sarcopenia is indeed elevated [25–27]. This phenomenon was observed in breast cancer [25, 28], hepatocellular carcinoma [29], medullary thyroid cancer [30], and colorectal cancer [31]. For example, patients with sarcopenia and medullary thyroid cancer had an increased average serum concentration of vandetanib (1037 ng/ml vs. 745 ng/ml, p = 0.04) [30]. Moreover, dose-limiting toxic reactions occurred more frequently in patients with sarcopenia than in patients with normal muscle mass (73 % vs. 14 %, p = 0.004) [30]. The observed relationships between sarcopenia and drug concentration in plasma can be explained by the fact that skeletal muscle is a significant component of lean body mass (LBM) [17, 23, 24]. LBM includes metabolically active tissue like the liver and kidneys, intracellular and extracellular water, skeletal muscle, and bone [17, 23, 24, 26]. Moreover, the entire LBM can be determined based on the muscle cross-sectional area [26]: LBM (kg) = 0.30 × (skeletal muscle area at L3 on CT (cm²)) + 6.06.

According to the literature, the chemotherapy dose per LBM is a strong predictor of DLT [23, 24]. To date, Sjøblom et al. have shown that the gemcitabine dose per kg LBM is associated with grade 3–4 hematological toxicity in patients with lung cancer [27]. Moreover, Williams et al. examined the pharmacokinetics and toxicity of 5-fluorouracil (5FU) in patients with colorectal cancer and determined that patients with grade 3/4 toxicity received a higher dose of 5FU per kg LBM [31]. Similar results were observed by Prado et al. for breast cancer [22, 25, 28]. The higher plasma concentration of the drug in patients with sarcopenia could be related to the fact that the chemotherapy dose is calculated on the basis of the body surface area (BSA). However, the BSA does not reflect body composition [22–24]. Moreover, patients with the same BSA have major differences in LBM [23, 24, 32].

In addition, an excessive dose of chemotherapeutic agents in patients with sarcopenia can be the result of decreased activity of the liver cytochromes involved in the metabolism of chemotherapeutic agents [17, 23, 24]. In an experimental study, a significant decrease in the activity of liver cytochromes was observed in rats with sarcopenia [33].

Interestingly, the relationship between DLT and sarcopenia can differ depending on the treatment setting. Curative chemotherapy is more aggressive than palliative chemotherapy and the risk of DLT in patients with sarcopenia is higher in the curative setting. More importantly, the relationship between sarcopenia and DLT depends on the treatment substances. The relationship between sarcopenia and DLT is greatest in patients undergoing kinase inhibitor therapy. Moreover, the effect of sarcopenia on treatment-based toxicity is lowest in patients treated with checkpoint inhibitors.

The exact reason for this is not yet clear. Various chemotherapeutic agents probably have a different distribution in the compartments of the body [22–24].

Further important aspects regarding the role of skeletal muscle in homeostasis are known. According to the literature, skeletal muscle functions like an endocrine organ in that it synthesizes and releases a specific group of cytokines and peptides, known as...
as myokines. There are multiple interactions between skeletal muscle and the immune system [34]. For example, patients with sarcopenia have a lower average number of CD8 + T-cells than patients without sarcopenia [34]. Skeletal muscle cells interact with immune cells, express the main histocompatibility complexes I and II and affect T-cell function [35]. Moreover, skeletal muscles produce myokines with immunological effects [36]. For example, interleukin (IL)-15 is a myokine that stimulates the proliferation and activation of natural killer cells and CD8 + T-lymphocytes [37]. Thus, intravenous administration of IL-15 resulted in a significant increase in circulating CD8 + T-cells and NK-cells in patients with various tumors [37, 38]. Theoretically, reduced musculature can result in the production of a smaller amount of myokines. Moreover, it was able to be shown that immunotherapy in combination with the administration of IL-15 extended the survival of mice with tumors [39]. A lower IL-15 level can presumably affect the efficacy of immunotherapy.

It is clear that the relationships between the clinical treatment result and skeletal muscle in oncology is complex and multifactorial. Further experimental studies are therefore needed to clarify the exact mechanisms of these interactions. Regardless of the physiological mechanisms, this information is very important for daily clinical practice and could be helpful for treatment selection. Therefore, the determination of sarcopenia based on a measurement during staging CT can be a next step on the path to personalized oncology.

To improve clinical treatment results, muscle mass and function can be positively influenced by various measures. For example, it was shown that fitness programs and protein-rich nutrition reduced sarcopenia in patients with gastric cancer and greatly improved the postoperative course [40]. Several studies indicate that reduced muscle density or myosteatosis plays a predictive role in various tumors [41, 42]. However, scientific data with sufficient evidence is only currently available for bronchial carcinoma, colorectal cancer, gastric cancer, and pancreatic cancer [42–45]. Moreover, the effect of myosteatosis on survival rates is lower than that of sarcopenia [42–45].

### Table 3 Effect of sarcopenia on survival in different tumors in a curative setting [15].

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Overall survival</th>
<th>Disease-free survival</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Univariable</td>
<td>Multivariable</td>
</tr>
<tr>
<td></td>
<td>analysis</td>
<td>analysis</td>
</tr>
<tr>
<td></td>
<td>HR</td>
<td>95 %CI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HNSCC</td>
<td>2.2</td>
<td>1.72–2.84</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>1.8</td>
<td>1.41–2.28</td>
</tr>
<tr>
<td>Bronchial carcinoma</td>
<td>2.9</td>
<td>2.31–3.62</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>2.0</td>
<td>1.47–2.73</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>1.9</td>
<td>1.68–2.12</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>1.8</td>
<td>1.57–2.14</td>
</tr>
<tr>
<td>Esophageal cancer</td>
<td>1.6</td>
<td>1.25–1.95</td>
</tr>
<tr>
<td>HCC</td>
<td>2.0</td>
<td>1.56–2.44</td>
</tr>
<tr>
<td>Urothelial carcinoma (kidney)</td>
<td>2.5</td>
<td>1.09–5.85</td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>1.6</td>
<td>1.37–1.94</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>1.6</td>
<td>1.19–2.24</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>1.7</td>
<td>1.25–2.33</td>
</tr>
</tbody>
</table>

HNSCC: head/neck squamous cell carcinoma; HCC: hepatocellular carcinoma.
In addition, individual publications were able to show that modern medical imaging post-processing methods, e.g., radio-mics, also allow sensitive analysis of muscle quality [46, 47]. The literature in this regard is based solely on individual studies. Therefore, definitive population-based statements currently cannot be made [46, 47].

Our analysis identified some deficiencies in the current literature regarding the clinical relevance of sarcopenia in oncology. Most publications are retrospective and thus have a corresponding bias. Moreover, the published studies only reported the results of regression analyses. Other important statistical values like negative predictive value were not analyzed.

**Conclusion**

Sarcopenia is a major clinical problem in oncology. It affects all relevant outcome parameters in oncology patients and should therefore be included in risk stratification. The condition of skeletal muscle should therefore be taken into consideration in radiology staging reports for oncology patients.

**Conflict of Interest**

The authors declare that they have no conflict of interest.
References

[37] Dubois SP, Miljkovic MD, Fleisher TA et al. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies. J Immunother Cancer 2021; 9 (4): e002193


